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Abstract
Background: The prognosis of patients suffering from WHO grade 3 and 4 astrocytic glioma
remains poor despite surgery, radiation therapy and the use of current chemotherapy regimen.
Indeed, the median survival of glioblastoma multiforme (WHO grade 4) patients is at best 14.6
month with only 26.5 percents of the patients still alive after 2 years and the median survival of
anaplastic astrocytomas (WHO grade 3) is 19.2 month. Recent evidence suggests that the
transcription factor NF-kappaB is constitutively expressed in malignant gliomas and that its
inhibition by drugs like Sulfasalazine may block the growth of astrocytic tumors in vitro and in
experimental models of malignant gliomas.
Design: ULg_GBM_04/1 is a prospective, randomized, double blind single-center phase 1–2 study.
A total of twenty patients with progressive malignant glioma despite surgery, radiation therapy and
a first line of chemotherapy will be recruited and assigned to four dosage regimen of Sulfasalazine.
This medication will be taken orally t.i.d. at a daily dose of 1.5–3–4 or 6 g, continuously until
complete remission, evidence of progression or drug intolerance. Primary endpoints are drug
safety in the setting of malignant gliomas and tumor response as measured according to
MacDonald's criteria. An interim analysis of drug safety will be conducted after the inclusion of ten
patients. The complete evaluation of primary endpoints will be conducted two years after the
enrolment of the last patient or after the death of the last patient should this occur prematurely.
Discussion: The aim of this study is to evaluate the safety and efficacy of Sulfasalazine as a
treatment for recurring malignant gliomas. The safety and efficacy of this drug are analyzed as
primary endpoints. Overall survival and progression-free survival are secondary endpoint.
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Background
The overall prognosis of malignant gliomas remains dis-
mal despite recent improvements in their surgery, radia-
tion therapy and chemotherapy [1-3]. Relapse usually
occurs within 9 month after presentation, median survival
barely reaches 1.6 years and less than 3% of the patients
survive more than 3 years [4]. These survival data outline
the urgent need to develop new treatment modalities and
if possible to base these new treatments on the biochemi-
cal characteristics of tumor cells.
Recent evidence demonstrates that the NF-kappaB tran-
scription factor is both over-expressed and constitutively
activated in astrocytic malignant gliomas [5-8]. As in a
variety of other tumor types, this activation contributes to
the growth, survival and chemoresistance of tumor cells
[9-11]. The potential benefit of NF-kappaB inhibition in
the treatment of malignant tumors has been recently
shown in multiple myeloma with the use proteasome
inhibitor PS-341 [12,13].
Sulfalsalazine is an anti-inflammatory drug used for dec-
ades to treat inflammatory bowel disease and severe forms
of rheumatoid arthritis [14]. It was shown to inhibit the
activation of NF-kappaB in a variety of models [15,16].
We have also shown that Sulfasalazine induces apoptosis
and inhibits the growth in glioblastoma cells but does not
harm normal astrocytes. It also significantly reduces the in
vivo growth of orthotopic xenografts of human malignant
gliomas in nude mice [6].
Since there is a remarkable need for new, specific treat-
ments for malignant gliomas and as the safety record of
the drug Sulfasalazine is good, we have initiated a phase
1–2 clinical study of this drug foir the treatment of pro-
gressive or recurrent malignant astrocytic tumors. The
working hypothesis is thus that Sulfaslazine should be
well tolerated by patients with recurrent or progressive
malignant glioma and could inhibit tumor progression.
Design
Study objectives
Primary objectives are twofold. First, this study will evalu-
ate the maximal daily oral dose of Sulfaslazine that is tol-
erated by patients with recurrent or progressive malignant
gliomas and will record the nature, frequency, possible
causality and severity of adverse events that occur during
treatment. The second primary objective is the assessment
of any clinical and/ or radiological response of individual
tumors to Sulfasalazine.
Overall and progression free survival following the initia-
tion of Sulfasalazine treatment are secondary objectives of
this study.
Regulatory issues and monitoring
This study protocol was designed by the Departments of
Neurosurgery and Human Genetics of the University Hos-
pital of Liège, Belgium (PAR -principal investigator). The
protocol was reviewed and approved by the Ethics Com-
mittee of the Faculty of Medicine of the University of Liège
(IRB file number 2004/185). It also underwent review and
approval by Belgian Federal Authorities (authorization
reference 548/03/05) and was granted the European Trial
database (EudraCT) number 2004-004392-11. It is spon-
sored by the Department of Neurosurgery, University
Hospital of Liège. It is funded by the Leon Frederic Fund,
which has neither access to the trial database nor right to
review the results prior to their publicatrion, and is not
otherwise involved in the study completion. The protocol
has been listed on the International Standard Rand-
omized Controlled Trial Number Register under number
ISRCTN45828668.
An independent adverse events monitoring commission
was set by the Ethics Committee and will review each seri-
ous adverse events and perform an interim analysis of the
results for the first ten patients in order to evaluate the
overall risk of the study and decide upon its further com-
pletion.
Study patients are covered by a medical liability insurance
contracted by the University Hospital of Liege according
to paragraph 29 of the Belgian Federal Law dated May 7,
2004. Medications are prepared and provided by the Liege
University Hospital Pharmacy. They are prepared just
before delivery to the patients and treatment refills are
provided every 30 days during follow-up visits. The rand-
omization table was set by the University of Liège Depart-
ment of Medical Statistics using commercially available
statistical software and directly provided to the hospital
pharmacist. The pharmacist will provide the correlation
between names and dosages to the independent review
committee at the time of interim analysis and to the prin-
cipal investigator at the time of final analysis.
Overall design
ULg_GBM_04/1 is a phase 1–2, single center, prospective,
randomized, double blind clinical study. To assess the
maximal tolerated daily dose of Sulfasalazine, 4 groups of
5 patients will be given 1.5, 3, 4.5 or 6 grams of this drug.
Sulfasalazine will be conditioned in similarly looking oral
caps for each group, four of which will be taken orally
three times per day. The randomization of patients
between groups is provided by the department of Statistics
of the Faculty of Medicine of the University of Liège and
the drug dosage is communicated only to the hospital
pharmacist who prepares and delivers the drug. In order
to facilitate the interim analysis of the data by the review
committee, the randomization algorithm was weighted soBMC Cancer 2006, 6:29 http://www.biomedcentral.com/1471-2407/6/29
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that 8 of the first 10 patients receive either the lowest or
the highest drug dosage. Neither the investigators nor the
patients are aware of the drug dosage that they provide/
receive.
The medication is to be given continuously until complete
remission or disease progression (as defined below) is
observed, serious adverse events occur, the patients
decides to withdraw from the study or regulatory authori-
ties decide to halt the study.
Inclusion criteria
Adult patients (age > 18 year) with recurrent or progres-
sive WHO grade 3 or 4 astrocytic gliomas after surgery,
standard radiation therapy and a first line of conventional
chemotherapy (e.g., Temozolomide, CCNU or BCNU) are
eligible for this study. Recurrence or progression prior to
inclusion are based on MacDonald's criteria [17].
Patients are thoroughly informed about the nature of their
disease, suspected prognosis, study background and
objectives and potential alternative treatments. This infor-
mation is provided both orally and in written form, prior
to obtaining written informed consent from the patient.
Upon consent, an experienced neuropathologist must
confirm the diagnostic of grade 3 or 4 astrocytic glioma
based on surgical specimen obtained previously (confer
supra: standard treatment).
Exclusion criteria
Patients will not enter the study if they present with ana-
plastic oligodendroglioma (WHO grade 3). Allergy to
sulfa drugs, porphyria, G-6-PD deficiency and psychiatric
disorder deemed incompatible with compliance to the
study also contra-indicate enrollment in ULg_GBM_04/1.
Creatinine > 15 mg/l, TGO> 200 UI/l or amylase > 150
UI/l are contra-indications as well.
ULg_GBM_04/1 is not open to pregnant or lactating
women.
Finally, patients may not have received any other experi-
mental medication within 30 days (and at least five drug
half-lives) prior to inclusion in this study, and cannot
concomitantly take mercaptopurine.
Drug dosage and study duration
Sulfasalazine will be given orally three times a day at total
doses of 1.5, 3, 4.5 or 6 grams. Four caps of drug are to be
taken with each meal. Sulfaslazine is to be taken continu-
ously until radiological evidence of tumor progression,
complete remission, or the development of serious or
intolerable adverse effects. The patient may at any
moment decide to discontinue his participation to the
study, although every effort will be made to be able to
carry on the follow-up. Finally, the independent review
committee may decide at any moment to end the study
based on safety issues.
Investigation schedule and evaluation of safety and 
efficacy
Patients with evidence of progression of WHO grade 3 or
4 astrocytic glioma will be considered for enrolment in
EudraCT 2004-004392-11. Informed consent will be
obtained and blood and urine will be obtained to assess
renal, liver and pancreatic function as well as RBC, WBC
and platelet counts. Beta-HCG will also be measured if the
patient is a female. Pathology will be reviewed and if
inclusion/ exclusion criteria are met, thorough medical
history, clinical exam and an inclusion MRI will be per-
formed. Sulfasalazine will be introduced within 10 days
of this screening visit. Follow-up visits are scheduled every
15 days for 3 months to monitor adverse events and con-
trol the evolution of blood tests. Urinalysis, MRI and clin-
ical follow-up are scheduled to occur every 30 days for the
duration of Sulfasalazine treatment. Clinical follow-up is
to be continued every 3 months after the end of Sulfasala-
zine treatment (Figure 1).
Safety will thus be evaluated by physical examination,
blood tests and urinalysis on a regular basis. Adverse
events will be recorded according to the NCI common
toxicity criteria (CTCAE) version 3.0. Serious adverse
events will be immediately reported to the independent
review committee.
Efficacy will be assessed primarily as a measure of tumor
volume changes. Tumor volume will be measured on
gadolinium-enhanced T1 weighted images performed
according to a standard protocol. Scans are scheduled to
be made immediately prior to inclusion and every month
after study enrollment. Volume changes will be evaluated
according to Mac Donald's criteria [17]. Additional effi-
cacy monitoring will be obtained through the follow-up
of neurological deficits.
Data analysis
Demographic, histological and clinical data of the
patients will be described. Adverse effects will be reported
qualitatively and classified according to body system,
nature, severity and frequency. Unexpected causes of
study drop-off will be reported and detailed. The inci-
dence and severity of adverse effects will be correlated
with drug dosage by means of contingency tests and linear
regression.
MacDonald criteria-based tumor response will be
reported and detailed with respect to its extent and dura-
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Tumor volume changes will be described and analyzed in
relation with drug dosage by means of contingency tests
and if possible linear regression.
Patients overall survival (OS) and progression-free sur-
vival (PFS) will be described and stratified by dose of Sul-
fasalazine according to the Log-Rank method. Kaplan-
Meier survival curves will also be provided.
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